CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma

Bart Burington, Peng Yue, Xiaoyan Shi, Ranjana Advani, Jeffrey T. Lau, Jenille Tan, Susanna Stinson, Jeremy Stinson, Thomas Januario, Sven De Vos, Stephen Ansell, Andres Forero-Torres, Grazyna Fedorowicz, Teddy T.C. Yang, Kristi Elkins, Changchun Du, Sankar Mohan, Nancy Yu, Zora Modrusan, Somasekar SeshagiriShang Fan Yu, Ajay Pandita, Hartmut Koeppen, Dorothy French, Andrew G. Polson, Rienk Offringa, Nancy Whiting, Allen Ebens, David Dornan

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


The primary function of B cells, critical components of the adaptive immune response, is to produce antibodies against foreign antigens, as well as to perform isotype class switching, which changes the heavy chain of an antibody so that it can interact with different repertoires of effector cells. CD40 is a member of the tumor necrosis factor superfamily of cell surface receptors that transmits survival signals to B cells. In contrast, in B cell cancers, stimulation of CD40 signaling results in a heterogeneous response in which cells can sometimes undergo cell death in response to treatment, depending on the system studied. We found an association between sensitivity to CD40 stimulation and mutation of the tumor suppressor p53 in a panel of non-Hodgkin's lymphoma cell lines. Consistent with p53's tumor suppressor role, we found that higher levels of intrinsic DNA damage and increased proliferation rates, as well as higher levels of BCL6, a transcriptional repressor proto-oncogene, were associated with sensitivity to CD40 stimulation. In addition, CD40 treatment-resistant cell lines were sensitized to CD40 stimulation after the introduction of DNA-damaging agents. Using gene expression analysis, we also showed that resistant cell lines exhibited a preexisting activated CD40 pathway and that an mRNA expression signature comprising CD40 target genes predicted sensitivity and resistance to CD40-activating agents in cell lines and mouse xenograft models. Finally, the gene signature predicted tumor shrinkage and progression-free survival in patients with diffuse large B cell lymphoma treated with dacetuzumab, a monoclonal antibody with partial CD40 agonist activity. These data show that CD40 pathway activation status may be useful in predicting the antitumor activity of CD40-stimulating therapeutic drugs.

Original languageEnglish (US)
Article number74ra22
JournalScience translational medicine
Issue number74
StatePublished - Mar 16 2011

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma'. Together they form a unique fingerprint.

Cite this